Actively Recruiting

Phase Not Applicable
Age: 22Years +
All Genders
ID07276529

Safety and Device Functionality of the Flexagon Self Forming Magnet Anastomosis Plus OTOLoc for Creating Ileo-colic, Colo-colonic and Colorectal Anastomoses in Patients Undergoing Surgical Procedures

Led by GI Windows, Inc. · Updated on 2026-04-13

20

Participants Needed

1

Research Sites

8 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of the Flexagon 25mm Self Forming Magnet (SFM) system plus OTOLoc device in creating side-to-side Ileo-colic, Colo-colonic, and side-to-side or end-to-side colorectal anastomoses in patients undergoing colon surgery. This prospective, single-center, single-arm early feasibility study aims to assess if the device can successfully create the target anastomosis without the need for reoperation related to the placement procedure, device, or anastomosis within 30 days. The study includes a roll-in training cohort and a primary analysis cohort to gather comprehensive safety data.

CONDITIONS

Brief Title

Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses

Who Can Participate

Age: 22Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 22 years or older at screening
  • Candidate for surgery requiring Right or Left Hemicolectomy, Sigmoidectomy, or Low Anterior resection with cardiac/medical clearance for surgery
  • Able to understand and sign informed consent document
  • American Society of Anesthesiologists (ASA) score less than IV at time of procedure
  • All cancer patients must have completed chemotherapy at least 2 months prior to procedure
  • Lives and intends to remain within a 150-mile radius of study center for the duration of the study
  • Able to refrain from smoking during study follow-up period
Not Eligible

You will not qualify if you...

  • Known or suspected allergy to silicone, nickel, titanium, or Nitinol
  • Body mass index (BMI) greater than 55 kg/m2
  • Uncontrolled diabetes with HbA1c greater than 10%
  • Congenital or acquired gastrointestinal tract anomalies that would prevent passing of the SFM magnet
  • Acute diagnosis of obstructed or perforated colon cancer at screening
  • Conditions contraindicating endoscopy or laparoscopy or history of failed endoscopy suggesting difficulty with magnet delivery
  • History of recurrent small bowel obstructions
  • Coagulation deficiency not corrected by treatment or platelet count below 50,000/µL
  • Moderate to severe renal disease or ongoing dialysis
  • Hyperkalemia, hypercoagulability, or prior venous thromboembolism/pulmonary embolism
  • Immunocompromised status including active malignancy treatment or advanced HIV
  • Congestive heart failure with ejection fraction less than 35% or significant arrhythmia except specified rhythms
  • Decompensated chronic obstructive lung disease
  • Active or suspected infection at surgical site or contaminated surgical wound
  • Contraindication to general anesthesia
  • Breast-feeding, pregnant, or planning pregnancy during follow-up
  • Participation in another clinical trial within past 30 days with investigational treatments
  • Considered inappropriate for trial inclusion by Principal Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Day of surgery

Participants undergo laparoscopic colon surgery using the Flexagon Self Forming Magnet Anastomosis Plus OTOLoc device to create side-to-side or end-to-side colorectal anastomoses under general anesthesia.

1 surgical procedure visit (in-person)

Post-operative Follow-up

Duration - Up to 60 days after surgery

Participants are monitored clinically after surgery to assess recovery and device safety at discharge and during follow-up visits.

4 visits (at discharge, Day 7, Day 30, and Day 60)

Trial Site Locations

Total: 1 location

1

Orlando Health

Orlando, Florida, United States, 32806

Actively Recruiting

Loading map...

Research Team

P

Peter J Lukin, BS

J

Jessica Musiak, BS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

A Phase 1/2a Study of the Safety, Tolerability, and Prelimin...

Castration-Resistant Prostate Cancer (CRPC)

Actively Recruiting

4 locations

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabe...

Metastatic Sarcoma

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here